Previous close | 195.53 |
Open | 197.95 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 197.46 - 198.82 |
52-week range | 166.56 - 247.57 |
Volume | |
Avg. volume | 2,863 |
Market cap | 395.723M |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | 0.36 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
RESEARCH TRIANGLE PARK, N.C., May 25, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life science industry, announced a groundbreaking partnership today with (RED), the organization co-founded by Bono and Bobby Shriver to fight AIDS and the injustices that enable pandemics to thrive, to support laboratory system strengthening and save lives.
RESEARCH TRIANGLE PARK, N.C., May 24, 2023--Global research and development activity in oncology remained at historically high levels in 2022, up 22% from 2018, and the global number of patients treated with approved medicines increased at an average of 5% annually over the same period, according to a new report from the IQVIA Institute for Human Data Science on Global Oncology Trends 2023. Over the last five years, a total of 115 novel active substances in oncology have launched globally; simul
INNOVATION PARK, N.C., May 18, 2023--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), priced an offering of $1,250,000,000 in aggregate principal amount of senior notes, which was upsized due to strong demand, consisting of $750,000,000 in aggregate principal amount of senior secured notes due 2028 (the "Senior Secured Notes") and $500,000,000 in aggregate principal amount of senior notes due 2030 (the "Senior Notes" and, together with t
INNOVATION PARK, N.C., May 18, 2023--IQVIA Holdings Inc. (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the "Issuer"), intends to raise $1,000,000,000 through an offering of senior secured notes due 2028 and senior notes due 2030 (collectively, the "Notes").
RESEARCH TRIANGLE PARK, N.C., May 11, 2023--IQVIA (NYSE:IQV) today announced that Sheetal Telang, vice president of Therapeutic Strategy, has been honored with the 2023 Rising Star award by the Healthcare Businesswoman's Association (HBA).
RESEARCH TRIANGLE PARK, N.C., May 02, 2023--The U.S. market for medicines grew by 5% in 2022, reaching a total value of $429Bn on a net price basis. This was driven by a range of factors, including an increase in health services utilization, which is now back to pre-pandemic levels, and the entry of new medicines into the market. Balancing these drivers of growth, was a lack of net price increases for branded drugs and patient out-of-pocket costs per retail prescription remaining under $10. This
RESEARCH TRIANGLE PARK, N.C., April 27, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended March 31, 2023.
RESEARCH TRIANGLE PARK, N.C., April 20, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the company has been recognized as a Leader in Customer Experience Platforms (CXP) by Everest Group for its Orchestrated Customer Engagement (OCE) platform.
RESEARCH TRIANGLE PARK, N.C., April 06, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its first-quarter 2023 financial results before the market opens on Thursday, April 27, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
RESEARCH TRIANGLE PARK, N.C., March 14, 2023--In 2022, global clinical trial activity remained resilient even as the COVID-19 pandemic stretched through the year, with a 1% decline in non-COVID trial activity compared to 2021. COVID-19 trials as a percentage of total trial activity dropped from 10% to 6% of the 5,756 total trials run in 2022. Non-COVID trial activity increased by 8% between 2019 and 2022, suggesting a restoration to pre-pandemic growth rates, according to a new report, Global Tr
RESEARCH TRIANGLE PARK, N.C., March 01, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Barclays Global Healthcare Conference in Miami, FL on Wednesday, March 15, 2023 at 9:30 a.m. ET.
RESEARCH TRIANGLE PARK, N.C., February 23, 2023--IQVIA (NYSE:IQV) has published its 2022 Environmental, Social and Governance (ESG) Report. The annual report provides a detailed account of the organization’s focus on reducing its environmental impact and commitment to accelerating positive outcomes for public health and patients.
RESEARCH TRIANGLE PARK, N.C., February 10, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended December 31, 2022.
RESEARCH TRIANGLE PARK, N.C., February 09, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s "World’s Most Admired Companies" list for the sixth consecutive year.
RESEARCH TRIANGLE PARK, N.C., January 31, 2023--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the pharmaceutical and broader life sciences industry, today announces the first life sciences industry collaboration with Alibaba Cloud in China. IQVIA and Alibaba Cloud, the digital technology and intelligence backbone of Alibaba Group, will be providing solutions hosted in Mainland China leveraging Salesforce on Alibaba Clou
RESEARCH TRIANGLE PARK, N.C., January 25, 2023--IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV) will announce its fourth-quarter and full-year 2022 financial results before the market opens on Friday, February 10, 2023. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
RESEARCH TRIANGLE PARK, N.C., January 18, 2023--The total spending and global demand for medicines will increase over the next five years to approximately $1.9 trillion by 2027, according to a new report titled Global Use of Medicines 2023 – Outlook through 2027 from the IQVIA Institute for Human Data Science.
Lasso, an IQVIA (IQV) business and provider of a leading healthcare marketing and analytics operating system, announced the integration of IQVIA's AIM XR (Audience Identity Manager® XR) into their operating system, giving over 4,000 medical publishers access to timely insights on campaign reach and effectiveness. Lasso's Measurement Suite is immediately available to all AIM XR partners.
Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and the airway resulting from cancer, trauma or birth defects, today announced that it had selected IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, as the contract research organization (CRO) to manage its first clinical
RESEARCH TRIANGLE PARK, N.C., November 10, 2022--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a long-term collaboration with Clalit, the largest health services organization in Israel, to launch the first Prime Site in the country.
RESEARCH TRIANGLE PARK, N.C., October 26, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today reported financial results for the quarter ended September 30, 2022.
RESEARCH TRIANGLE PARK, N.C., October 24, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Credit Suisse Annual Healthcare Conference in Rancho Palos Verdes on Tuesday, November 8, 2022 at 12:10 p.m. ET (9:10 a.m. PT).
RESEARCH TRIANGLE PARK, N.C., October 06, 2022--Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
RESEARCH TRIANGLE PARK, N.C., October 03, 2022--IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV) will announce its third-quarter 2022 financial results before the market opens on Wednesday, October 26, 2022. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com.
RESEARCH TRIANGLE PARK, N.C., September 28, 2022--IQVIA (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry, today announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation.